Ocugen

Ocugen Charts a Three-Year Path to FDA Filings With $112M War Chest and a Novel Gene Therapy Platform

kashif hafeez -

Ocugen’s Refinancing Cuts Debt Burden as Gene Therapy Data Buoy Outlook — But Stock Slips on Dilution Worries

kashif hafeez -

Ocugen’s Pipeline Accelerates into a Pivotal Summer as Convertible Debt Fuels and Frays Investor Sentiment

angelina -

Ocugen’s Third Quarter: A Crucible of Clinical Data and Capital Concerns

Ocugen Navigates a Critical Juncture with Cash and Clinical Catalysts

angelina -

Analyst Confidence Rises for Ocugen’s Gene Therapy Pipeline

angelina -

Ocugen Sets Ambitious Regulatory Timeline for Gene Therapy Pipeline

Brett Shapiro -

Ocugen Set to Unveil Full Phase 2 Trial Results for Key Gene Therapy

Brett Shapiro -

Analyst Sentiment Shifts as Ocugen’s Clinical Pipeline Gains Momentum

kashif hafeez -

Ocugen’s Aggressive Development Pipeline Faces Critical Data Readouts

kashif hafeez -

Ocugen Shares Surge on Analyst Optimism and Upcoming Clinical Catalysts

Analyst Optimism Fuels Momentum for Ocugen’s Clinical Pipeline

angelina -

Ocugen Reports Key Clinical and Financial Milestones

Brett Shapiro -

Ocugen Achieves Key Milestone in Gene Therapy Trial

angelina -

A Pivotal Week for Ocugen as Financial and Clinical Catalysts Converge

angelina -
123Page 1 of 3